How mathematical modeling could contribute to the quantification of metastatic tumor burden under therapy: insights in immunotherapeutic treatment of non-small cell lung cancer

Table 1 Monoclonal antibodies

Antibody	Type	Year of approval (FDA)	Molar Mass M_i [kDa]	Approved Dosages	Half-life \(t^{1/2}_{i}\) [d]	Sources
Atezolizumab	humanized	2016	145	1200mg q3w	27	[70, 71]
Avelumab	human	2017	143	800mg q2w	6.1	[72, 73]
Durvalumab	human	2017	146	10mg/kg q2w	18	[74, 75]
Nivolumab	human	2014	146	240mg q2w or 480mg q4w	26.7	[76, 77]
Pembrolizumab	humanized	2014	146	200mg q3w or 400mg q6w	22	[78, 79]
Cemiplimab	human	2018	144	350mg q3w	19.4	[80, 81]

Currently approved monoclonal antibodies used as immunotherapeutics targeting the PD-1 pathway. The application cycle length l used in the model is determined from the dosage, e.g. the expression “q3w” reads “every three weeks”, thus l=3

ISSN: 1742-4682